RxDoctor Payments Data

Mark Sanchez

Reproductive Endocrinology · Tampa, FLNPI 1851377642

Payments from drug & device makers

What this record shows

14 manufacturers reported payments, led by Luye Pharma (USA) Ltd. at 58.2% of the total. 2025 is the largest year on record at $2,194, more than ten times the $144 reported in 2019.

$3,438in general payments, 2019–2025

Across 61 payments — averaging $56.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Luye Pharma (USA) Ltd.$2K
  • Ferring Pharmaceuticals Inc.$545
  • Organon$403
  • Sumitomo Pharma America, Inc.$75
  • Myovant Sciences Inc.$74
  • AbbVie$72
  • plus $270 from 8 others
$773,902in research payments, 2019–2025

Across 63 payments — averaging $12,284 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • IBSA Institut Biochimique SA$707K
  • Bayer$51K
  • Merck$8K
  • Exeltis, USA Inc.$8K

What the payments were for

  • Consulting fees$2,00058%
  • Food & beverage$1,43842%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,438 in reported general payments places this provider in the 85th percentile of 89 reproductive endocrinology providers in Florida.

See all reproductive endocrinology providers in Florida

Other reproductive endocrinology in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →